| Assessment Status |
Awaiting full HTA submission from Applicant |
| HTA ID |
23026 |
| Drug |
Efgartigimod alfa |
| Brand |
Vyvgart® |
| Indication |
Efgartigimod alfa is indicated as an add-on to standard therapy for the treatment of adult patients with generalised Myasthenia Gravis who are anti-acetylcholine receptor antibody positive. |
| Rapid review commissioned |
12/05/2023 |
| Rapid review completed |
19/06/2023 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of efgartigimod alfa compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
28/06/2023 |
| Pre-submission consultation with Applicant |
07/11/2023 |
